本帖最后由 老马 于 2013-3-13 13:43 编辑 # F/ X9 P4 w# l7 ?2 f [
, Q; o) t) `, L) ^ g/ l# y( b健择（吉西他滨）+顺铂+阿瓦斯汀
0 H! P# Y- Z, Z" \ Gemzar +Cisplatin + Avastin+ E& p' P" J0 v1 u
http://annonc.oxfordjournals.org/content/21/9/1804.full# _+ E6 \, _" U& f
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
" c1 ~* G# p) U& Z- [- ]Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. & h) H) {' b7 W3 E; D9 P
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. . y6 a6 ?% V/ `5 Z" S
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 825)
9 r* h+ T, A* ], \
华为网盘附件：
; U7 K$ R9 W$ @* h& c) \) ?9 W【华为网盘】ava.JPG/ z r1 _9 S/ J
|
显身卡
